Evidence map›Paper›PMID 29677173›Full record

ReviewInternational journal of molecular sciences2018

What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies.

Yann Guillermin, Jonathan Lopez, Kaddour Chabane, Sandrine Hayette, Claire Bardel, Gilles Salles, Pierre Sujobert, Sarah Huet

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Sequencing of Cutaneous Squamous Cell Carcinoma Primary Tumors and Patient-Matched Metastases RevealsJID innovations : skin science from molecules to population health · 2022
    Article
  5. The Impact of COVID-19 Pandemic in Portuguese Cancer Patients: A Retrospective Study.International journal of environmental research and public health · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yann GuillerminCentre Léon Bérard, Service d'Hématologie Clinique, 69008 Lyon, France. yannguillermin@orange.fr.
Jonathan LopezHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire de Biochimie et Biologie moléculaire, 69495 Pierre-Bénite CEDEX, France. jonathan.lopez@chu-lyon.fr.
Kaddour ChabaneHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'Hématologie, 69495 Pierre-Bénite CEDEX, France. kaddour.chabane@chu-lyon.fr.ORCID 0000-0002-6715-5133
Sandrine HayetteCancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée LIGUE Contre le Cancer, 69008 Lyon, France. sandrine.hayette@chu-lyon.fr.
Claire BardelHospices Civils de Lyon, Service de Biostatistique-bioinformatique et plateforme de séquençage haut débit NGS-CHU Lyon, 69677 Bron CEDEX, France. claire.bardel@chu-lyon.fr.
Gilles SallesCancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée LIGUE Contre le Cancer, 69008 Lyon, France. gilles.salles@chu-lyon.fr.
Pierre SujobertCancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée LIGUE Contre le Cancer, 69008 Lyon, France. pierre.sujobert@chu-lyon.fr.
Sarah HuetCancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée LIGUE Contre le Cancer, 69008 Lyon, France. sarah.huet@chu-lyon.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with subsequent prognostic and therapeutic implications. The biology of cancer is becoming increasingly deciphered and it is clear that therapy needs to be individually tailored. Whilst translational research plays an important role in lymphoid malignancies, few guidelines exist to guide biologists and routine laboratories through this constantly evolving field. In this article, we review the challenges of interpreting HTS in lymphoid malignancies and provide a toolkit to interpret single nucleotide variants obtained from HTS. We define the pre-analytical issues such as sequencing DNA obtained from formalin-fixed and paraffin-embedded tissue (FFPE), the acquisition of germline DNA, or the bioinformatic pitfalls, the analytical issues encountered and how to manage them. We describe the main constitutional and cancer databases, their characteristics and limitations, with an emphasis on variant interpretation in lymphoid malignancies. Finally, we discuss the challenges of predictions that one can make using in silico or in vitro modelling, pharmacogenomic screening, and the limits of those prediction tools. This description of the current status in genomic interpretation highlights the need for new large databases and international collaboration in the lymphoma field.

Indexed as

Computational BiologyFormaldehydeHigh-Throughput Nucleotide SequencingHumansLymphomaMutationParaffin EmbeddingSequence Analysis, DNATissue FixationFormaldehydelymphoid malignanciesnext-generation sequencingvariant interpretation

Identifiers

PMID29677173
PMCPMC5979354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.